本瑞利珠单抗治疗重度嗜酸性哮喘的真实世界疗效
治疗48周后年化急性发作率降低72.8%,口服激素剂量中位数从10 mg降至0 mg,86%患者达到应答标准,13.8%为无应答者。
要点
- 本瑞利珠单抗治疗48周后年化急性发作率降低72.8%,43.8%患者无急性发作。
- 基线使用口服激素者中51.4%可停用口服激素,中位剂量降至0 mg。
- 86%患者达到应答标准,39%达到超级应答标准,13.8%无应答。
核心结论
- 在大型真实世界重度嗜酸性哮喘队列中,本瑞利珠单抗使所有临床结局指标均获显著改善,仅少数患者无应答。
研究设计与样本
- 每次给药访视记录急性发作史、口服激素剂量、肺功能、ACQ6和mAQLQ评分。
- 应答定义为治疗48周后年化急性发作率或口服激素剂量降低≥50%,超级应答定义为无急性发作且未使用口服激素。
主要发现
- 48周时年化急性发作率从治疗前一年的4.92±3.35次/年降至1.34±1.71次/年(P<.001),降低72.8%。
- 57例(43.8%)患者无急性发作。
- 使用口服激素的74例(56.9%)中,每日泼尼松龙剂量中位数从10 mg(IQR 5-20 mg)降至0 mg(IQR 0-5 mg;P<.001),38/74例(51.4%)停用口服激素。
- ACQ6评分、mAQLQ评分和FEV1均有临床和统计学显著改善。
- 51例(39%)达到超级应答标准,112例(86%)达到应答标准,18例(13.8%)无应答。
关键数值与推荐
- 应答:治疗48周后年化急性发作率或口服激素剂量降低≥50%。
- 超级应答:无急性发作且未使用口服激素。
- 超级应答 vs 其他应答者的最优回归模型包含与强嗜酸性表型和较轻疾病相关的基线特征。
临床怎么用
- 本瑞利珠单抗在真实世界重度嗜酸性哮喘患者中可显著降低急性发作率和口服激素剂量,多数患者可达应答。
- 治疗前强嗜酸性表型和较轻疾病可能提示更高的超级应答概率。
- 无应答者中需注意慢性气道感染或抗药抗体导致的血嗜酸性粒细胞计数升高。
局限性
- 单中心真实世界研究,结果外推需谨慎。
- 无应答者仅18例,相关分析样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Benralizumab is an IL5-receptor monoclonal antibody licensed for the treatment of severe eosinophilic asthma (SEA). It has demonstrated efficacy in clinical trials in reducing asthma exacerbation rates and maintenance oral corticosteroids (mOCSs). RESEARCH QUESTION: What is the real-world effectiveness of benralizumab and what baseline characteristics are associated with response to therapy? STUDY DESIGN AND METHODS: We assessed outcomes in all SEA patients who began benralizumab treatment at our specialist center. At each dosing visit, exacerbation history, mOCS dose, spirometry, and Asthma Control Questionnaire (ACQ6) and Mini-Asthma Quality of Life Questionnaire (mAQLQ) scores were recorded. Response to treatment was defined as a reduction of ≥ 50% in annualized exacerbation rate (AER) or in mOCS dose after 48 weeks of treatment. Super response was defined as zero exacerbations and no mOCSs for asthma. RESULTS: One hundred thirty patients were included in the analysis. At 48 weeks, a 72.8% reduction in AER was noted, from 4.92 ± 3.35 per year in the year preceding biologic treatment to 1.34 ± 1.71 per year (P < .001), including 57 patients (43.8%) who were exacerbation-free with benralizumab. In those receiving mOCSs (n = 74 [56.9%]), the median daily prednisolone dose fell from 10 mg (interquartile range, 5-20 mg) to 0 mg (interquartile range, 0-5 mg; P < .001), and 38 of 74 patients (51.4%) were able to discontinue mOCS therapy. Clinically and statistically significant improvements were found in ACQ6 scores, mAQLQ scores, and FEV1. Overall, 51 patients (39%) met the super responder definition and 112 patients (86%) met the responder definition. The optimal regression model of super responders vs other responders included baseline characteristics associated with a strongly eosinophilic phenotype and less severe disease. Eighteen patients (13.8%) were nonresponders to benralizumab. Evidence of chronic airway infection was observed in 6 of 18 patients, and an increase in the blood eosinophil count consistent with the development of anti-drug antibodies was observed in 5 of 18 patients. INTERPRETATION: In a large real-world SEA cohort, benralizumab led to significant improvements in all clinical outcome measures. A lack of response was seen in a minority of patients and should be a focus for future investigation.
引用
- Kavanagh JE, Hearn AP, Dhariwal J, et al. Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma. Chest. 2020. PMID: 32882249. doi:10.1016/j.chest.2020.08.2083
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。